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Emerging  technologies,  like  nanotechnology,  are often  hailed  as  transformative  technologies  that  will
not only  help  the rich,  but be  used  to decrease  poverty  and inequality.  In order  to  overcome  many of  the
challenges  associated  with  developing  products  for poor communities,  especially  medicines  for  the poor,
institutions setup  organizations  called  public  private  partnership  (PPPs).  This study  examines  whether
PPPs  are  developing  nanotechnology  to make  medicines  for  diseases  of  poverty  (DoP).  PPPs  are  the  main
actors researching  medicines  for DoP  and  if they  are  not  involved  with  nanotechnology  research,  then
it  is unlikely  that  nanomedicines  for DoP  will  be  developed.  Through  interviews  and  website  content
analysis,  this  study  ﬁnds  that  there  are  only  a few  PPPs  doing  nanomedicine  research.  Many  of  the  PPPsanotechnology
iseases of poverty
nclusive innovation
are  worried  that the technology  is  too  expensive  and  it will  take  too  long  to bring  nanomedicines  to
the  market.  To  increase  the  likelihood  that  emerging  technologies,  like  nanotechnology,  will  be used  to
mitigate  poverty,  policy  makers  can  do several  things  like  change  the  patent  laws  to  encourage  innovation
on  technologies  for the poor,  increase  research  funding  in  areas  that  address  development,  and  move
pro-poor  technologies  quickly  through  the  regulation  process.
© 2016  The  Author.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Many of the world’s deadly diseases have been eradicated
hrough a variety of technologies and social improvements. Some
iseases were addressed by better medications, treatment reg-
mens and vaccines, while other diseases were eradicated due
o improved cleanliness standards that prevented pestilence
rom spreading. Despite the improvements in overall health, the
dvancements are not evenly distributed. Many medical discover-
es only target diseases of the very rich and other medicines are too
xpensive for impoverished communities to purchase. At one point
cholars estimated that there was a “10–90 gap” in health research
ecause they found that less than 10% of healthcare research and
evelopment (R&D) was on diseases that affect 90% of the world’s
opulation (Murray et al., 2012). Today the gap is not 10–90, but
here are many diseases that predominantly affect the poor that
eceive little R&D funding (Moran, 2005).
Most scholars identify about 40 disease of poverty (DoP) (Moran
t al., 2010; World Health Organization, 2010) and the healthcare
E-mail addresses: thomas.woodson@stonybrook.edu, tswoodson@gmail.com
ttp://dx.doi.org/10.1016/j.respol.2016.04.005
048-7333/© 2016 The Author. Published by Elsevier B.V. This is an open access article u
http://creativecommons.org/licenses/by-nc-nd/4.0/).literature attributes a portion of global health inequality to the lack
of a proﬁtable market associated with DoP medicines (Chataway
et al., 2010; Moran et al., 2010; Widdus, 2001). Scholars reason
that biotechnology and pharmaceutical companies will not develop
new medicines to target DoP if they cannot recoup their R&D
expenses, and as a result, there is less R&D and medicines for DoP.
To overcome the small market for DoP treatments, scholars
believe that it is necessary to develop special organizational struc-
tures called public-private partnerships (PPPs) (Chataway et al.,
2010; Moran et al., 2010; Widdus, 2001). PPPs can improve the
DoP medicine market by connecting pharmaceutical suppliers with
customers and lowering the barriers to entry so pharmaceuti-
cal companies can develop and sell medicines for DoP. PPPs also
provide research funds, link companies to government health orga-
nizations, participate in manufacturing and assist with distribution
and marketing (Glennerster et al., 2006; Widdus, 2001). These
efforts can spur drug development on DoP, make the current
medicines more accessible, and lead to inclusive innovations.
One new health technology that some scientists believe will rev-
olutionized healthcare is nanotechnology. Scientists hope medical
applications of nanotechnology (nanomedicine) will lead to things
like targeted drug delivery systems, nearly instantaneous disease
detection sensors and stronger, yet ﬂexible, prosthetics (Invernizzi,
nder the CC BY-NC-ND license
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006). However, nanotechnology, and other emerging technolo-
ies, only have viable futures if there is a market for them (Cozzens
t al., 2010). If there is no market for a technology, then companies
o not have an incentive to develop and sell them. Yet, the mar-
et for DoP medicines is unclear because companies are unlikely to
ecoup their research expenses and make a proﬁt on medicines for
iseases that affect the poor (Kremer, 2002). Therefore, there is an
nteresting intersection between PPPs, nanomedicine and inclusive
nnovation. According to current academic theory, emerging tech-
ologies, which could have an impact on the poor, will only be used
o address DoP if a market exists. PPPs can help build and main-
ain a market, and as a consequence, entrepreneurs and scientists
ill use emerging technologies, like nanomedicine, for inclusive
evelopment (Glennerster et al., 2006).
This study investigates the role of PPPs for DoP medicine devel-
pment and whether they are researching nanomedicine. It adds
o the literature on PPPs by considering the extent that this organi-
ational structure can develop emerging technologies for inclusive
evelopment. How do PPPs decide the types of projects to pursue?
o PPPs think nanomedicine is a viable ﬁeld? Is there evidence of
 relationship between PPPs and emerging technologies? I use a
ixture of primary and secondary sources to understand the moti-
ations of PPPs, their research priorities, and importantly, whether
PPs can overcome market deﬁciencies to provide emerging tech-
ologies for inclusive development. This paper begins by giving an
verview of the relevant literature and the research methods. Then,
 discuss the research ﬁndings and policy implications.
. Literature review
.1. Public private partnerships
PPPs are not new institutions; rather, governments have part-
ered with private organizations to provide public services for
undreds of years. For example, the Dutch East India Company
as a partnership between the Dutch government and industry
o encourage world-wide trade and during World War  II, govern-
ents heavily relied on the private industry to provide supplies
nd services for the war movement (Wettenhall, 2005). Despite
he prevalence of government and non-government partnerships,
he term public-private partnership was ﬁrst used about 40 years
go (Bovaird, 2004) and since then, it has grown in prominence.
PPs span sectors and have a variety of functions like policy design,
olicy evaluation and monitoring, implementation, capacity build-
ng, activism and resource mobilization (Bovaird, 2004; Brinkerhoff
nd Brinkerhoff, 2011).
One heavily cited deﬁnition of PPPs is “working arrangements
ased on a mutual commitment (over and above that implied in any
ontract) between a public sector organization with any organiza-
ion outside of the public sector” (Bovaird, 2004). This deﬁnition is
road and it allows PPPs to have assorted organizational structures
anging from partnerships between national government agencies
nd companies to partnerships between local government depart-
ents and community group.
These type of organizations form for a variety of reasons. First,
he complexity and interconnectivity of problems prohibit a single
rganization from accomplishing their goals, so in order to succeed,
rganizations must partner together (McQuaid, 2000; Van Ham and
oppenjan, 2001). The need to partner due to increased complexity
s especially relevant for organizations working with highly scien-
iﬁc emerging technologies. These technologies are at the forefront
f knowledge, and a variety of sectors must share knowledge in
rder to develop them (Cozzens et al., 2010).
A second reason that organizations form PPPs is that a group
f organizations can better overcome market deﬁciencies than a 45 (2016) 1410–1418 1411
single actor (McQuaid, 2000; Van Ham and Koppenjan, 2001). For
example, some innovations have high technical risk that prevent
them from being economically attractive, while other innovations
have low monetary return. PPPs can circumvent these barriers by
spreading the risk of failure over multiple parties and projects
(Greve, 2006).
Partnerships also improve the economies of scale of R&D and
pool talents across different sectors (Bovaird, 2004). Most health
PPPs have expert scientiﬁc boards from industry, academia and
non-proﬁt organizations that assist managers to choose research
portfolios that align with the goals of the organization. The boards’
consider the cost and feasibly of projects to decide whether to
pursue them (Munoz et al., 2015). In contrast, independent orga-
nizations may  not have the personnel and ﬁnancial resources
to manage, evaluate, and implement multiple highly technical
projects (Moran et al., 2010).
However, not all scholars think that PPPs are beneﬁcial for inclu-
sive development. Miraftab describes PPPs as Trojan Horses that
hide unequal power relationships and lead to community part-
ners being marginalized by the dominant partner. Asymmetric
power relationships are especially prone to occur with low-income
communities because poor constituents have fewer resources to
make their voices heard (Miraftab, 2004). Rather than thinking of
PPPs as a panacea to problems, Miraftab suggests that PPPs focus
on improving social, economic and cultural conditions (Miraftab,
2004). Simply forming a PPP does not guarantee equitable out-
comes.
Since there are so many types PPPs, this paper focuses on a
subset of PPP’s called product development partnerships (PDPs).
Chataway et al. deﬁnes PDPs as a “technology push initiative
aimed at providing new science and technology based products for
neglected diseases” (Chataway et al., 2009). The majority of health
PPPs/PDPs began around 1999 (Munoz et al., 2015; The Economist,
2013), and at that time, several factors converged to create a public
buzz to address DoP. In 1999, there was substantial public out-
rage directed at pharmaceutical companies because they refused
to provide low-cost HIV medicines to victims in poor countries. In
response to the negative publicity, many of the big pharmaceu-
tical companies began researching medicines for DoP and giving
their technology to researchers working on these diseases (The
Economist, 2013). Moreover, in 2000 the United Nations launched
the Millennium Development Goals (MDGs) and increased the vis-
ibility of DoP. This made the world community more responsive
to the needs of the poor and it put public pressure on countries
to ﬁnd solutions for these issues. Similarly, celebrity activists, like
Bono and Angelina Jolie, and large non-proﬁt organizations, like
the Bill and Melinda Gates Foundation, highlighted the importance
of global health and many of these activists viewed PPPs as a the
vehicle to leverage the advantages of the private sector to address
poverty issues (Cohen, 2006).
PPPs are now the principal organizations developing medicines
for DoP (Grace, 2010; Moran et al., 2010; Munoz et al., 2015). Moran
estimates that in 2004 75% of R&D projects for neglected diseases
were conducted by PPPs (Moran, 2005) and that 14 PPPs spent $262
million on neglected disease R&D in 2007 (Moran et al., 2010). In
addition, by 2010 PPPs brought 10 new health products to market
and it had another 122 treatments in the pipeline (Grace, 2010).
Health PPPs are described as “ ‘system integrators’ that leverage
the resources and capabilities of a network of a public, philan-
thropic and private sector partners” (Munoz et al., 2015). Chataway
et al. ﬁnd that prominent PPPs are knowledge brokers and inte-
grators that drive innovation, stimulate R&D and negotiate among
other organizations in the biomedical research innovation system
(Chataway et al., 2007). However, previous studies do not inves-
tigate whether PPPs actually develop emerging technologies for
poverty alleviation and there is some doubt that PPPs can really
1412 T.S. Woodson / Research Policy 45 (2016) 1410–1418
Table 1
List of PPP/PDP studied.
List of formal PPPs
Aeras International AIDS Vaccine Initiative (IAVI)
Buruli Vac Consortium International Partnership for Microbicides (IPM)
Consortium for Parasitic Drug Delivery International Vaccine Institute (IVI)
Drugs for Neglected Diseases initiative (DNDi) Malaria Vaccine Initiative (MVI)
European Vaccine Initiative (EVI) Medicines for Malaria Venture (MMV)
European and Developing Countries Clinical Trials Partnership Meningitis Vaccine Project (MVP)
European Solutions Enterprise on Neglected Diseases Novartis Institute for Tropical Diseases
Foundation for Innovative New Diagnostics (FIND) One World Health (OWH)
Global Solutions for Infectious Diseases Program for Appropriate Technology in Health (PATH)
Global Alliance for TB Drug Development (TB Alliance) Sabin Vaccine Institute
Global Alliance for Vaccines and Immunisation The Vizier Project
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Innovative Vector Control Consortium (IVCC)
evelop emerging technologies cheaper than traditional pharma-
eutical companies (Grace, 2010).
.2. Emerging technology and nanotechnology
There is no universal deﬁnition of emerging technologies; how-
ver, they can be described as technologies that have fast and recent
rowth; transition to something new; have prominent impact; and
ased on scientiﬁc innovations and breakthroughs (Cozzens et al.,
010; Rotolo et al., 2015). Emerging technologies are important for
conomic growth because they overthrow status quo technologies
ith time saving devices, create new industrial opportunities and
evive dying economies (Avila-Robinson and Miyazaki, 2011; Day
nd Schoemaker, 2000). Because new and emerging technologies
re so central to economic growth national governments, indus-
ries, and universities invest a lot of resources in R&D for emerging
echnologies.
One emerging technology that has received a great deal of
ttention over the past decade is nanotechnology, which “is
he understanding and control of matter at dimensions between
pproximately 1 and 100 nanometers” (National Science and
echnology Council, 2011). At the nanoscale matter has different
roperties, like conductivity or reactivity, and these unique proper-
ies make it possible to do novel research and create new products.
ome of the most promising nanotechnology products are related
o energy systems, metal alloys, healthcare and computer chips.
The nanotechnology revolution began around 2000 with the
stablishment of the USA National Nanotechnology Initiative (NNI).
t initially received $475 million and over the past 15 years, its fund-
ng has steadily grown (United States National Nanotechnology
nitiative, 2015). Other countries made similarly large investments
n nanotechnology and by 2004 about 62 countries, of which 12
ere lower income countries, had some type of nanotechnology
nitiative (Maclurcan, 2010).
A large subset of the nanotechnology ﬁeld is nanomedicine.
he idea of nanomedicine can be traced back to Richard Feynman,
ho is often attributed as the father of nanotechnology (Freitas,
005). In his famous speech, there’s “Plenty of Room at the Bot-
om”, Feynman describes a future where little robots would be
urgeons inside the body and doctors could permanently implant
evices to help organs function (Feynman, 1959). Today, scien-
ists are trying their best to realize Feynman’s dream, and they
ave developed things like diagnostic tools, drug delivery sys-
ems and implants/prosthetics (Freitas, 2005; Invernizzi, 2006).
anomedicine is still in its infancy, but in 2011, nanomedicine was $50.1 billion market with expectations that it would grow to a
97 billion market by 2016 (Evers, 2012).
Most nanomedicine R&D occurs in the USA and Europe on
iseases like cancer or diabetes (Woodson, 2012). However,arma
rculosis Vaccine Initiative (TBVI)
: Special Programme for Research and Training in Tropical Diseases (WHO/TDR)
nanomedicine is not only relevant for non-communicable diseases.
Scientists could use the technology to development treatments
for infectious diseases, like malaria and tuberculosis, and other
diseases that predominantly impact the poor (Sosnik and Amiji,
2010). Unfortunately, much of the inequality in health R&D per-
sists in nanomedicine R&D (Woodson, 2012). So, even though
nanomedicine has received signiﬁcant attention in the health inno-
vation system, DoP nanomedicines are still are a small part of the
research agenda (Sosnik and Amiji, 2010; Woodson, 2012).
3. Methods
This study uses two  main sources of data, PPP websites and semi
structured interviews, to examine PPP nanomedicine research. By
using both the websites and interviews, I capture more informa-
tion that can be used to triangulate the results to make stronger
conclusions. I started the analysis by examining the websites of
the various PPPs. These websites are very detailed, and most PPPs
websites discuss their funding sources, research portfolios and the
reasons their organization is best suited for DoP research. Also,
the websites usually have internal search engines that allowed me
to search explicitly for information related to nanotechnology and
poverty alleviation. Once the data was collected and downloaded,
the relevant text from each website was  uploaded into Nvivo (a
qualitative data management software) to be coded and analyzed.
The list of PPPs studied in this project, see Table 1, was derived from
other studies on health PPPs (Grace, 2010; Moran et al., 2010).
Next, I interviewed scientists and PPP managers. I chose these
actors because managers have the most information about the mis-
sion of the PPP and the way the organization sets research priorities.
Scientists, on the other hand, understand technical details about
research portfolios and the potential of nanotechnology. The inter-
views took place from June 2013 to July 2014 and were 30 min
to one hour long. Table 2 lists the interview questions. After con-
ducting an interview, I transcribed and uploaded it into Nvivo for
analysis. I conducted a total of 14 interviews. Eleven of the inter-
views were with managers and scientists at 10 different PPPs. Three
of the interviews were with university scientists who partner with
PPPs. Therefore, out of the 28 PPPs I considered in this study, I
interviewed someone from 10 of the PPPs and collected website
information for 24 of them. Four of the PPPs were defunct or had
merged with another organization at the time of the study.
Once I collected the data, I used web-based content analy-
sis methods to analyze the data and extract useful information
(Herring, 2010; McMillan, 2000; Weare and Lin, 2000). The codes
used to sort the data are found in Table 3. The initial codes were
developed from the literature on PPPs, but additional codes were
added as other topics became apparent.
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Table  2
Interview questions.
Interview Questions
Introduction/Background What is your background?
What do you do within your organization?
Give a brief overview of your organization?
Research/Focus What is your research?
Who  funds your research?
How did you choose your research area?
What are some successes you have had in your research?
Who  are your research partners?
How long have you been working in this area?
What types of project will you do in the future?
Nanomedicine Are  you doing any work in nanomedicine?
Why  (or why  not) are you doing work in nanomedicine?
Do you think nanomedicine is useful for DoP R&D?
PPP Do you consider your organization a public private partnership? If so why?
What is the structure of your PPP?
Who  funds the PPP?
Where do PPPs ﬁt within research and drug discovery?
Are PPPs necessary to ﬁnd medicines for DoP?
How does your organization use patents, and publications?
How does your PPP choose its research foci?
Do you think PPPs are the new normal for drug development
Do  you collaborate/talk with other PPPs?
All PPPs seemed to spring up at the same time. Do you have any clues why?
DoP In  your opinion what are the most problematic DoP?
What research areas are necessary to reduce the burden of disease from DoP?
Table 3
Content analysis coding.
Codes Code Explanation
Disease of poverty Any mention of a disease of poverty
Diseases Any mention to a non-DoP
Drug Delivery Any mention to drug delivery systems
Funding information on who funds the PPP or how much money they have
Future any reference to the future (i.e. the future of the PPP or DoP research)
Governance Information on the governance structure of the PPP
History History/origins of the PPP start?
International Any mention to countries working with PPP
Model Explanation of the PPP model and why  it is important
Nanotechnology Any reference to nanotechnology
Partners Who  is the PPP working with?
Portfolio Information on the research projects
Publishing/patenting Information on publishing and patenting habits of organization or researcher.
Scientist Any reference to a speciﬁc researcher
ogy
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tSensors Any reference to sensor technol
Skills Mentioning a speciﬁc skill of sci
The websites and interviews provide rich data, but like all
esearch methods, these techniques have limitations. One major
isadvantage of the interviews is that I had a small sample size.
t was difﬁcult getting PPP managers and scientists to respond to
y phone calls and emails. The non-response rate could bias my
esults and limit the conclusions that I can draw from the analysis.
lso, the websites have a lot of information, but they only give the
erspective of the PPPs. To mitigate this bias, I interviewed a few
xperts that do not work for PPPs in order to get their opinion about
he organizations and DoP nanomedicines.
. Results
.1. Importance of PPPsThe ﬁrst observed trend in the study is that PPPs are keen to
ommunicate that they are different than pharmaceutical compa-
ies and their unique mission allows them to pursue technologies
hat traditional pharmaceutical companies would not consider. For or the PPP
example, Medicines for Malaria Ventures (MMV) devotes sections
of their webpage to describing PPP and PDPs. They even feature
video interviews and animations explaining the importance of PDPs
(http://www.mmv.org/). They say that PDPs
“. . .act as a facilitator, bringing dedicated sources of funding and
know-how to committed researchers so they can collaborate on
the right projects to fulﬁll the objectives of the PDPs mission. The
speciﬁc objectives of individual PDPs vary, but the basic mission is
the same: to develop pharmaceutical products for use as a public
good to address the health needs of vulnerable populations in the
developing world.”
PPPs view themselves as changing the traditional model of phar-
maceutical drug manufacturers in order to provide medicines for
the poor and underserved populations. They employ terms like
“uniquely positioned” or “bridges” to show their centrality for DoP
R&D. PPPs highlight that the complexity of the healthcare system
requires organizations to work together and PPPs are able to ﬁll
that gap. One manager explains that,
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“. . . if you go back 50 years ago you had one chemist and a doc-
tor who would try a medicine out on patients. Now you have a
whole range of skills from chemists to biologists to toxicologists
(who make sure things are safe). It’s become much more of a team
effort.”
This manager emphasizes the myriad of skills necessary for drug
evelopment and a single organizational entity cannot do every-
hing. Different organizations have to work together because one
ctor cannot accomplish the goal.
Not only do PPPs view themselves as bridging a skill gap
etween sectors, but they think they bring together actors with
istinct incentives. Industry and academia have differing reward
ystems and structures. Industry is concerned with generating a
roﬁt, while academics are more concerned with producing top
esearch. As one manager says,
“Academic cultures and industrial cultures are by deﬁnition
different. . . Which means the goal needs to be a concrete goal for
the industry which is not the same for the academic environment
who can have a lot of beneﬁt from excellent publications but will
never lead to a concrete drug that will be brought to the market.”
This manager explains that the different cultures between phar-
aceutical ﬁrms and academic institutions affect their research
nd partnerships. However, PPPs can bridge the two cultures and
ake it easier to work together.
A second factor that PPPs use to justify their competitive advan-
age to develop emerging technologies is that they believe they are
he best organizations at picking technology for DoP medicines.
PPs maintain that academia and industry have incentives that
ock them into certain research trajectories and prevent them from
hoosing a viable research path. PPPs, on the other hand, believe
hat they are better judges of successful research lines because they
re more impartial.
“The venture capital industry is all about putting the right projects
together and funding them for as long as they need and giving them
all the money they need up to key decision points and then stopping.
It’s a very different funding model than say an academic crowd
where you write a proposal and get money for ﬁve years. And at
the end of ﬁve years you have to explain what you’ve did with it.
So I think when you look at the big consortia [PPP] model, its better
suited to the venture capital model. Let pay be based on rewards
and stop if it’s not working”
The PPPs manage and “prune” research portfolios in order to
aximize the potential of the research. If a certain research path is
 dead-end, PPPs feel that they can quickly end them.
Finally, PPPs repeatedly say that they ﬁx the lack of commercial
nterest for DoP R&D. One PPP’s website says that one of their main
urposes is to address this market failure.
“PDPs address the lack of commercial incentive to undertake
R&D for vaccines, diagnostics, and drugs for neglected diseases
of the developing world. They use public and philanthropic funds
to engage the pharmaceutical industry and academic research
institutions in undertaking R&D for diseases of the developing
world that they would normally be unable or unwilling to pursue
independently.  . .”
This PPP discusses how they use funds from several sources in
rder to bring together participants to pursue the same project.
 manager at a PPP explains that partnerships lower the risk to
ompanies. If an individual company tries to develop a novel drug
reatment and it fails, then they could lose a lot of money. How-
ver, by partnering with a PPP, the company is less exposed to poor
esearch portfolios because their R&D expenses are pooled with
ther investors. The manager explains that, 45 (2016) 1410–1418
“In order for a company to make an investment in developing a
technology and providing it. . .the technology has to make sense
ﬁnancially for them and PPP B ﬁlls in the gap is by helping to de-risk
the process”
4.2. Types of PPPs
Another ﬁnding that became apparent during this study is that
there are different types of PPPs and the organizational structure
inﬂuences whether they research emerging technologies. From the
analysis, health PPPs can be divided into two broad groups: R&D
PPPs; and advocacy, education and medicine pricing PPPs. Some of
the larger PPPs perform all of these roles, but often the partner-
ships specialize in either R&D or the downstream aspects of the
health innovation system. The R&D PPPs are especially interesting
for this study because they were the only PPPs that were developing
DoP nanomedicines. The advocacy, education, and pricing PPPs, on
the other hand, implemented innovative supply chain or education
programs to decrease health inequality.
The R&D PPPs can be further divided into in-house R&D lab
and R&D managers. The in-house R&D PPPs function like aca-
demic research labs. These PPPs are awarded research grants from
large foundations and government agencies to pursue a particular
medicine for a disease. One key resource of in-house R&D PPPs is
that they share administration resources in order to reduce costs.
A manager of an in-house R&D PPP says that,
“We  leverage the fact that we maximize the resources because we
are imbedded in institutions that already have a lot of resources. For
instance I don’t have to worry about ethic reviews because we  uti-
lize the IRB of our institutions . . . therefore, the funding we receive is
much better utilized because we don’t have to recreate the bureau-
cratic and administrative system. . ..  It’s like having a biotechnology
company embedded within an academic institution.”
This manager believes that their close afﬁliation with a univer-
sity helps the organization be more effective with their resources
because they can utilize the university’s research infrastructure.
The other type of R&D PPPs act as knowledge facilitators. Rather
than doing all the research in-house, these PPPs contract the work
to other scientists. A typical scenario for a knowledge facilitator is
that they will ﬁnd research grants and then redistribute the money
to other research labs. For example a PPP manger says,
“Well for each project we have to write a proposal to a donor and
get funding for a speciﬁc scope of work. . . And then depending on
the role of PPP X, it might be managing the project or grant out the
money to the collaborators”
Another PPP mangers explains that
“PPP A’s R&D expenditure is generally not direct expenditure, but
is in the form of grants and contracts with external parties who
perform certain tasks at its request”
Both of these PPPs act as project managers and intermediary for
grant agencies.
In the interviews I asked PPPs about their choice to outsource
R&D projects instead of using in-house R&D labs. Most of the knowl-
edge facilitator PPPs responded that outsourcing R&D saves money
and allows them to better manage the projects. Another beneﬁt
is that outsourcing lets the PPP focus its attention on managing
the research portfolio instead managing a lab. The in-house R&D
PPPs were normally started as university spin-offs and they con-
tinued on particular R&D pathways. There was  not a discernable
relationship between the type of R&D PPP and whether they are
developing nanomedicines. Both in-house R&D and R&D manage-
ment PPPs conducted nanomedicine research. However, it is clear
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hat only PPPs that concentrate on R&D, as opposed to advocacy
nd pricing, will even consider pursing emerging technologies like
anomedicine.
.3. Nanotechnology and PPPs
A key goal of this paper is to understand the role that PPPs
lay in advancing research on emerging technologies that could
educe poverty and inequality. Overall, the managers and scien-
ists give a wide range of answers on the reasons they choose to
tudy nanotechnology for DoP research. Several PPPs are actively
ngaged with nanotechnology and believe that it is a smart
esearch path, while other partnerships think nanomedicine is
ot good for DoP medicines. The sample can be loosely divided
nto pro-nanotechnology and anti-nanotechnology organizations.
he pro-nanotechnology organizations are working on novel drug
elivery systems, like encapsulating medicine inside nanoparticles
or TB or HIV/AIDs medicines, and creating special bandages that
lowly release medicine.
Some of the pro-nanomedicine scientists are very positive about
he potential of the technology. One optimistic scientists says that
“Nanoparticles are not only [good] for delivery drug, but you
can imagine many things. There is no limit to how you imagine
nanoparticles. . . [there] are so many applications of nanotechnol-
ogy because you can make smart nanoparticles· · ·You can track
down your drug, do diagnostics. . . you can do many things”
In general, pro-nanotechnology PPPs believe that the current
reatments are not ideal and that nanotechnology can be helpful for
oP medicines (Sosnik and Amiji, 2010). New nanomedicines could
horten treatment times, have fewer side effects and simplify the
reatment regimen. This is especially important in poor regions.
Another pro-nanomedicine interviewee thinks nanotechnology
ad potential, but the initial optimism of the technology has waned.
er PPP partners with nanotechnology scientists for drug delivery
ystems, but nanotechnology is a small part of her R&D portfolio.
he manager says that,
“I think with every new technology there’s always a spike of ini-
tial excitement and enthusiasm . . ..  And then with more work and
knowledge it becomes more tempered. People realize nano may be
good for certain things but it’s not going to make sense for other
things”
This PPP manager believes that nanotechnology could be useful
n developing medicines for DoP, but nanomedicine will be one
iece of a multi-faceted approach.
The anti-nanomedicine interviewees think the technology
ould be useful for other medical areas, but not for DoP. Their
ain criticism focuses on the cost and regulatory constraints of
he technology. They worry that nanomedicines will be too expen-
ive to manufacture for drugs that require a very low price point. A
anager at an HIV PPP says that
“We  have to be pennies on the dollar for what our products are
and governments to buy them and have them a part of their public
health programs. Any technology that requires sophisticated man-
ufacturing or high cost manufacturing is. . . though probably viable
from a medical perspective, not viable from a cost perspective”
This manager is not pursuing nanomedicine for HIV because she
elieves that the high costs of fabricating nanoparticles and get-
ing them regulated would be too expensive for low cost HIV/AIDS
edicine. Interestingly, individuals and managers working on DoP
dvocacy and price controls were less likely to think nanomedicine
s useful for DoP. 45 (2016) 1410–1418 1415
Finally, I asked the pro-nanotechnology PPPs about the regula-
tory challenges posed by nanotechnology. Most of them responded
that they are excited about the potential of nanomedicine for DoP,
despite the challenges. One PPP manager said
But hey if someone doesn’t start, then the data is never compiled.
So even though we don’t know if any of these things in our hands
will become licensed, but we’re evaluating them because we need
to ensure that we have different alternatives.”
This manager sees the value of having a variety of medicines.
She is excited about the potential of nanomedicine R&D despite
the challenges.
4.4. Funding
An additional aspect that impacts the ability of PPPs to do DoP
nanomedicine research is that the organizations must get fund-
ing to do the research. The PPPs in this study receive their funding
from a mixture of government and private sector funds. However,
the most prominent funders of PPPs are large foundations like the
Bill and Melinda Gates Foundation (BMGF). Almost all the PPPs in
this study have funding from the BMGF and in most instances the
foundation provided the initial seed funding for the PPP. Similarly,
other studies ﬁnd that the BMGF dominates PPP funding. Moran
et al. estimate that the BMGF provided about 50% of formal PPP
funding in 2007 (Moran et al., 2010). Other than the BMGF, PPPs
received funding from large donors like the USA National Institutes
of Health (NIH), the Rockefeller Foundation, the US  Agency for Inter-
national Development (USAID), and western European countries
like the UK, Germany, and Denmark. These organization invest a
lot in R&D, but if they are not interested in pursuing nanotechnol-
ogy, or other emerging technologies, then it is very difﬁcult for PPPs
to pursue these lines of research.
PPPs have a different relationship with corporate funding. Some
PPPs receive major support from big pharmaceutical companies
(big pharma), like Merck or Johnson & Johnson, while others tend
to stay away from big pharma. One PPP says that big pharma is not
interested in their organization because
“There is not a lot of commercial interest in the vaccines that we
have in our portfolio versus something like malaria that may have
multiuse”
This PPP manager expresses that big pharma is not interested in
their R&D because the corporate partner does not think it can proﬁt
from the R&D on obscure DoP.
A common complaint by the PPP managers is that there is a
lack of overall funding for R&D and it is difﬁcult to fund the basic
operations of their organizations. During the recession in the late
2000s, all the donors, including large government agencies, slowed
their outlays because they did not have extra money to fund non-
proﬁt activities. One scientists says that
“It seems to me that it’s getting harder to do the work because of
the funding environment. It’s probably getting harder for everyone
to work”
Getting money for research on DoP is especially difﬁcult. The
same scientist goes on to say that ﬁnding research money for DoP
R&D is
“. . .a  struggle because you look around and there are cancer
grants from the university and things such as that and it’s harder
to ﬁnd opportunities other than the NIH to keep your [DoP]
research going”
Without sufﬁcient research donations it is impossible for PPPs
to pursue R&D for inclusive development.
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As a consequence, several PPPs mention that they are target-
ng new sources of funding. One PPP in this study receives funding
rom the Fundación Carlos Slim, a foundation that has not tradi-
ionally supported biomedicine research, and the PPP is targeting
igh net worth individuals to support speciﬁc projects. Another
unding diversiﬁcation strategy that was mentioned is that PPPs are
eeking out foundations that will provide matching funds for their
urrent fundraising campaigns. The manager reasons that donors
ill be more likely to give if they are ensured that the money will be
atched by another donor and the matching donor may  feel more
onﬁdent in their gift if other organizations vetted and support the
roject. A third money saving strategy for PPPs is that they use
nother organizations’ lab and equipment instead of outﬁtting their
wn facilities. In this strategy, money may  not exchange hands, but
PPs can receive a lot of beneﬁts. One PPP manager explains that
“. . .the NIH will give us money, where we don’t directly get the
money, but we’ll say we need to have this tested and they’ll do it
without charging us and without giving us money.”
This type of in-kind work is a creative way to fund DoP research.
he last strategy that was mentioned by PPPs is that they negoti-
te free supplies, compounds and formulas from pharmaceutical
ompanies. Again, this saves PPPs money and lets them focus their
esources on other aspects of their organization.
Finally, a major challenge expressed by PPPs is that donor orga-
izations often put strict restrictions on the activities that they can
o with the research money. For example, the donor may  require
hat funds only be spent on a particular HIV project and prohibit
ransferring it to another experiment. In addition, many donors
ave very onerous reporting requirements. A PPP director says that,
“So reporting back to donors is extremely time consuming. Each
donor is very speciﬁc about what their money can be spent on and
we have to report back. That’s an incredibly involved effort”
To comply with all the requirements, PPPs must hire full time
taff members to handle the grant logistics. For smaller PPPs this is
 big burden.
Therefore, given all the funding and reporting challenges facing
PP, they may  not be able to research on emerging technologies
imply because they do not have enough money to do this type of
ork.
.5. Patents and publications
Another insight that is not discussed in other research on PPPs
s that these organizations actively publish their ﬁndings. On their
ebsites PPPs often cite their high publication rates as measures
f success. One PPP report highlights that one of their main accom-
lishments in 2012 was publishing over 25 peer-reviewed journal
rticles that year.
PPPs publish for a variety of reasons. First, PPPs want to dissem-
nate their information. A manager at a large PPP says that
“Publishing and disseminating information is a key part of what we
do. We  have principals of global access that we work with. Global
access means that the technology we work on should be accessible
as well as the information that we generate should be accessible.
So we typically strive to publish our work as much as possible and
build that into our agreements with our partners.”
This manager expresses that sharing information is a key part
f her organization’s strategy and that publishing is a major part
f that effort. Their dissemination strategy makes it easier for
esearchers in developing countries to access the results and use the
nding in their own research. This helps nanotechnology become
ore accessible to less afﬂuent nations. 45 (2016) 1410–1418
Patenting is more complicated for PPPs than publishing. Each
PPP approaches patenting slightly differently and PPPs have non-
disclosure agreements that prevent them from sharing details
about their IP and licensing arrangements (Munoz et al., 2015).
However, a major theme expressed by the PPPs is that they use
patents to protect themselves. Several PPPs worry that other orga-
nizations could prevent them from working on projects or steal
their IP if they do not proactively patent their technology. One
manager said,
“We  approach the patenting aspect mostly to protect not because
we foresee having some royalties generated. We  protect mostly so
that we can make sure no one interferes with us advancing this
program”
Another way PPPs ensure that they have the necessary access to
intellectual property (IP) is that they partner with biomedical com-
panies on projects. In these partnerships, PPPs and pharmaceutical
companies will develop special agreements that allow non-proﬁt
organizations to develop medicines for DoP without paying licens-
ing fees. The pharmaceutical company retains the rights to use the
technology in wealthy nations, but the PPP can use the technology
for humanitarian purposes. One PPP website explains that
“Industry partners assign all rights to PPP F for royalty-free use of
their technology in the public and private non-proﬁt sectors in high
endemic countries, while the industry partner retains distribution
rights for developed countries and the private sector in developing
countries. This enables the partner to recover R&D  costs and to
create the returns needed to develop new technologies.”
PPP F explains that having different patent protection for differ-
ent markets has allowed it to work with more companies.
“Our IP model has been successfully validated with industry part-
ners and has contributed to an important and increasing number
of contracts signed with large and small-sized companies.”
PPPs learned to navigate patent hurdles in order to protect
themselves and develop new technologies. These tactics are very
helpful for PPPs to fully develop emerging technologies for inclusive
development.
5. Conclusions/policy implications
From the interviews and website content analysis, I can draw
two major conclusions about PPPs and their ability to conduct
research and commercialize emerging technologies for inclusive
development. First, the analysis conﬁrms that health PPPs are cen-
tral to the health innovation system for DoP research because
they act as knowledge facilitators, utilize resources across sec-
tors and wisely prune research portfolios to prioritize the most
promising technologies. The advantages of PPPs allow them to
overcome some of the barriers that dissuade the private sector from
developing medicines for these diseases. Second, I conclude that
the unique advantages of PPPs help them explore nanomedicines
for DoP but PPPs cannot overcome all the barriers of developing
nanomedicines, and other emerging technologies, for consumers
in developing countries. Even if PPPs solve the technical challenges
associated with developing inclusive emerging technologies, there
are still obstacles with funding, regulations, and patents that can
derail technology development and diffusion for marginalized
groups. Given these conclusions, what type kind of policies could
encourage PPPs to conduct R&D on emerging technologies for inclu-
sive development?
One solution to encourage R&D for inclusive innovations, like
nanotechnology, is that government regulators could offer fast
track approval processes for technologies that help impoverished
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ommunities in order to ensure that the technology reaches the
arket quickly. Fast-track approval gives PPPs more certainty that
heir novel products will not languish behind walls of regulations.
hese types of policies might seems easy to implement, but they
ace many ethical hurdles because regulators cannot authorize
ubstandard products for low-income communities. However, if
cientists robustly test the medicines, then they can ensure the
roducts come to market quickly and safely. For example, the
DA could augment the “animal rule” so that more vaccines and
edicines for DoP can apply for this exemption.
In addition, policymakers can to adopt special incentives and
unding programs to encourage pro-poor research. One study ﬁnds
hat poverty related diseases cause 13.8% of global disease bur-
en, but only receive 1.34% of health related R&D expenditure (von
hilipsborn et al., 2015). R&D expenditure should be raised to match
he global disease burden. These changes will not only help PPPs,
ut it will encourage universities and companies to invest in R&D
hat decreases poverty.
Third, PPPs need to diversify their funding sources to ensure
hat they are not overly dependent on a few donors, like the BMGF,
or their income. They should target a wide range of foundations,
ational governments, companies and high net worth individuals.
nless PPPs can ﬁnd stable sources of funding, then this organiza-
ional model will not be a viable tool to encourage more R&D on
merging technologies for poverty alleviation.
Alongside ﬁnding new sources of funding, PPPs should encour-
ge donors to develop one reporting standard so that PPPs have
ore time and money to spend on R&D. This suggestion will
ace some resistance because it decreases donor control over their
ontributions. However, if PPPs propose a strong, yet uniform,
eporting mechanism, then it is possible that funding organizations
ill consider a change.
Finally, this study ﬁnds that PPPs are concerned that compa-
ies will steal their innovations and prevent them from developing
echnologies, and as a result, PPPs spend a great deal of money
nd time developing defensive patents. PPPs mentioned that the
urrent patent system limits their ability to develop medicines for
oP. However, reforming IP rights for emerging technologies is very
omplicated. There are numerous papers on this issue and often
cholars give competing advice based on their intellectual tradi-
ions (Feachem and Sachs, 2002; Global Forum for Health Research,
007; Kremer, 2002). Webber and Kremer write that
“Patent legislation represents a careful balance . . . Proposals to
alter the existing balance should be regarded with caution. Under-
mining patent protection could discourage innovative activity on
the part of industry, while strengthening patent protection could
come at the expense of reduced access” (Webber and Kremer,
2001).
Despite competing policy recommendations, one common sug-
estion is to loosen the patent laws for low-income countries and
or medicines that target DoP (Kremer, 2002). For example, the
atent code could allow non-proﬁt organizations, like PPPs and
niversities, to license IP for a signiﬁcantly reduced fee if the orga-
ization agrees to design and sell that product only to those living
elow the poverty line. This strategy allows research institutions
he access to the necessary IP to develop emerging technologies
ithout going through as many hurdles. In lieu of such reforms,
PPs made special deals with pharmaceutical companies in order to
ave access to compounds for medicine and vaccine development.
hough this strategy has worked, it is highly dependent on the
argess of big pharmaceutical companies. Changing the patent sys-
em would allow PPPs to be more effective and make it more likely
hat they will develop other emerging technologies for developing
ountries. 45 (2016) 1410–1418 1417
Science and technologies innovations, like fertilizer or com-
puters, have spawned industrial revolutions and improved the
economic conditions of people around the world. It is the hope
that emerging technologies, like nanotechnology, will not only
lead to new industrial transformations, but also decrease poverty
and inequality. Given that many past innovations have actually
increased inequality (Woodhouse and Sarewitz, 2007), it neces-
sary to re-conceptualized and create institutions to ensure that
poor, marginalized communities also beneﬁt from emerging tech-
nologies. PPPs are one category of institutions that can develop
emerging technologies to decrease poverty and inequality, but they
will not be the silver bullet to guarantee that emerging technology
will be inclusive.
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